2.84
+0.02(+0.71%)
Currency In USD
| Previous Close | 2.82 |
| Open | 2.8 |
| Day High | 2.97 |
| Day Low | 2.75 |
| 52-Week High | 3 |
| 52-Week Low | 0.66 |
| Volume | 1.12M |
| Average Volume | 1.39M |
| Market Cap | 264.47M |
| PE | -1.6 |
| EPS | -1.78 |
| Moving Average 50 Days | 2.07 |
| Moving Average 200 Days | 1.47 |
| Change | 0.02 |
If you invested $1000 in Caribou Biosciences, Inc. (CRBU) since IPO date, it would be worth $174.02 as of October 21, 2025 at a share price of $2.84. Whereas If you bought $1000 worth of Caribou Biosciences, Inc. (CRBU) shares 3 years ago, it would be worth $294.61 as of October 21, 2025 at a share price of $2.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference
GlobeNewswire Inc.
Aug 25, 2025 8:05 PM GMT
BERKELEY, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive of
Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 28, 2025 8:00 PM GMT
BERKELEY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive off
Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference
GlobeNewswire Inc.
May 06, 2025 8:00 PM GMT
BERKELEY, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive off